Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
BMJ ; 380: e072003, 2023 03 29.
Article in English | MEDLINE | ID: mdl-36990505

ABSTRACT

OBJECTIVE: To determine the relative efficacy of structured named diet and health behaviour programmes (dietary programmes) for prevention of mortality and major cardiovascular events in patients at increased risk of cardiovascular disease. DESIGN: Systematic review and network meta-analysis of randomised controlled trials. DATA SOURCES: AMED (Allied and Complementary Medicine Database), CENTRAL (Cochrane Central Register of Controlled Trials), Embase, Medline, CINAHL (Cumulative Index to Nursing and Allied Health Literature), and ClinicalTrials.gov were searched up to September 2021. STUDY SELECTION: Randomised trials of patients at increased risk of cardiovascular disease that compared dietary programmes with minimal intervention (eg, healthy diet brochure) or alternative programmes with at least nine months of follow-up and reporting on mortality or major cardiovascular events (such as stroke or non-fatal myocardial infarction). In addition to dietary intervention, dietary programmes could also include exercise, behavioural support, and other secondary interventions such as drug treatment. OUTCOMES AND MEASURES: All cause mortality, cardiovascular mortality, and individual cardiovascular events (stroke, non-fatal myocardial infarction, and unplanned cardiovascular interventions). REVIEW METHODS: Pairs of reviewers independently extracted data and assessed risk of bias. A random effects network meta-analysis was performed using a frequentist approach and grading of recommendations assessment, development and evaluation (GRADE) methods to determine the certainty of evidence for each outcome. RESULTS: 40 eligible trials were identified with 35 548 participants across seven named dietary programmes (low fat, 18 studies; Mediterranean, 12; very low fat, 6; modified fat, 4; combined low fat and low sodium, 3; Ornish, 3; Pritikin, 1). At last reported follow-up, based on moderate certainty evidence, Mediterranean dietary programmes proved superior to minimal intervention for the prevention of all cause mortality (odds ratio 0.72, 95% confidence interval 0.56 to 0.92; patients at intermediate risk: risk difference 17 fewer per 1000 followed over five years), cardiovascular mortality (0.55, 0.39 to 0.78; 13 fewer per 1000), stroke (0.65, 0.46 to 0.93; 7 fewer per 1000), and non-fatal myocardial infarction (0.48, 0.36 to 0.65; 17 fewer per 1000). Based on moderate certainty evidence, low fat programmes proved superior to minimal intervention for prevention of all cause mortality (0.84, 0.74 to 0.95; 9 fewer per 1000) and non-fatal myocardial infarction (0.77, 0.61 to 0.96; 7 fewer per 1000). The absolute effects for both dietary programmes were more pronounced for patients at high risk. There were no convincing differences between Mediterranean and low fat programmes for mortality or non-fatal myocardial infarction. The five remaining dietary programmes generally had little or no benefit compared with minimal intervention typically based on low to moderate certainty evidence. CONCLUSIONS: Moderate certainty evidence shows that programmes promoting Mediterranean and low fat diets, with or without physical activity or other interventions, reduce all cause mortality and non-fatal myocardial infarction in patients with increased cardiovascular risk. Mediterranean programmes are also likely to reduce stroke risk. Generally, other named dietary programmes were not superior to minimal intervention. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42016047939.


Subject(s)
Cardiovascular Diseases , Myocardial Infarction , Stroke , Humans , Cardiovascular Diseases/prevention & control , Network Meta-Analysis , Risk Factors , Myocardial Infarction/prevention & control , Stroke/prevention & control , Diet, Fat-Restricted
2.
Syst Rev ; 12(1): 39, 2023 03 14.
Article in English | MEDLINE | ID: mdl-36918997

ABSTRACT

BACKGROUND: The health effects of dietary fats are a controversial issue on which experts and authoritative organizations have often disagreed. Care providers, guideline developers, policy-makers, and researchers use systematic reviews to advise patients and members of the public on optimal dietary habits, and to formulate public health recommendations and policies. Existing reviews, however, have serious limitations that impede optimal dietary fat recommendations, such as a lack of focus on outcomes important to people, substantial risk of bias (RoB) issues, ignoring absolute estimates of effects together with comprehensive assessments of the certainty of the estimates for all outcomes. OBJECTIVE: We therefore propose a methodologically innovative systematic review using direct and indirect evidence on diet and food-based fats (i.e., reduction or replacement of saturated fat with monounsaturated or polyunsaturated fat, or carbohydrates or protein) and the risk of important health outcomes. METHODS: We will collaborate with an experienced research librarian to search MEDLINE, EMBASE, CINAHL, and the Cochrane Database of Systematic Reviews (CDSR) for randomized clinical trials (RCTs) addressing saturated fat and our health outcomes of interest. In duplicate, we will screen, extract results from primary studies, assess their RoB, conduct de novo meta-analyses and/or network meta-analysis, assess the impact of missing outcome data on meta-analyses, present absolute effect estimates, and assess the certainty of evidence for each outcome using the GRADE contextualized approach. Our work will inform recommendations on saturated fat based on international standards for reporting systematic reviews and guidelines. CONCLUSION: Our systematic review and meta-analysis will provide the most comprehensive and rigorous summary of the evidence addressing the relationship between saturated fat modification for people-important health outcomes. The evidence from this review will be used to inform public health nutrition guidelines. TRIAL REGISTRATION: PROSPERO Registration: CRD42023387377 .


Subject(s)
Diet , Dietary Fats , Fatty Acids , Nutrition Policy , Public Health , Humans , Diet/adverse effects , Diet/methods , Dietary Fats/adverse effects , Meta-Analysis as Topic , Systematic Reviews as Topic , Fatty Acids/adverse effects , International Health Regulations
3.
Heart Rhythm ; 17(9): 1472-1479, 2020 09.
Article in English | MEDLINE | ID: mdl-32438018

ABSTRACT

Chloroquine and hydroxychloroquine are now being widely used for treatment of COVID-19. Both medications prolong the QT interval and accordingly may put patients at increased risk for torsades de pointes and sudden death. Published guidance documents vary in their recommendations for monitoring and managing these potential adverse effects. Accordingly, we set out to conduct a systematic review of the arrhythmogenic effect of short courses of chloroquine or hydroxychloroquine. We searched on MEDLINE and Embase, as well as in the gray literature up to April 17, 2020, for the risk of QT prolongation, torsades, ventricular arrhythmia, and sudden death with short-term chloroquine and hydroxychloroquine usage. This search resulted in 390 unique records, of which 41 were ultimately selected for qualitative synthesis and which included data on 1515 COVID-19 patients. Approximately 10% of COVID-19 patients treated with these drugs developed QT prolongation. We found evidence of ventricular arrhythmia in 2 COVID-19 patients from a group of 28 treated with high-dose chloroquine. Limitations of these results are unclear follow-up and possible publication/reporting bias, but there is compelling evidence that chloroquine and hydroxychloroquine induce significant QT-interval prolongation and potentially increase the risk of arrhythmia. Daily electrocardiographic monitoring and other risk mitigation strategies should be considered in order to prevent possible harms from what is currently an unproven therapy.


Subject(s)
Betacoronavirus , Coronavirus Infections/drug therapy , Death, Sudden/etiology , Hydroxychloroquine/therapeutic use , Long QT Syndrome/etiology , Pneumonia, Viral/drug therapy , Torsades de Pointes/etiology , Antimalarials/therapeutic use , COVID-19 , Coronavirus Infections/complications , Humans , Pandemics , Pneumonia, Viral/complications , SARS-CoV-2 , COVID-19 Drug Treatment
4.
J Diabetes Metab Disord ; 19(2): 1835-1843, 2020 Dec.
Article in English | MEDLINE | ID: mdl-33520864

ABSTRACT

BACKGROUND & OBJECTIVES: The current evidence base regarding the impact of propolis consumption on lipid profile in humans is equivocal. Thus, we sought to investigate the impact of propolis consumption on anthropometric indices and lipid profile in this meta-analysis. METHODS: Cochrane Library, Scopus, PubMed, and Web of Science electronic databases were searched up to December 2019. A random-effects model used to pool effect size. The leave-one-out method used to conduct sensitivity analysis. RESULTS: Five RCTs were included in this study. Our findings indicated a significant decrease in triglyceride (TG) (WMD: -3.91 mg/dl, 95% CI: -4.22, -3.60), and a significant increase in high-density lipoprotein (HDL) (WMD: 3.41 mg/dl, 95% CI: 0.05, 6.76), however, for body mass index, weight, cholesterol (CL), and low-density lipoprotein (LDL), no significant alterations were evident. CONCLUSION: This study revealed that consumption of propolis is associated with a reduction in TG levels, in addition to an increase in HDL levels. Nevertheless, additional research is required to further delineate the relationship between propolis consumption and lipid profile.

SELECTION OF CITATIONS
SEARCH DETAIL
...